# A Clinical Study of Sotatercept (MK-7962) in People With Combined Postcapillary and Precapillary Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction (MK-7962-041)

Study · id `cardio:ct-nct07839585` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07839585](<https://clinicaltrials.gov/study/NCT07839585>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT07839585

Browse, organ or system: Heart; Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 352 participants.

## Technical summary

Registry record NCT07839585. Randomized; quadruple masking; primary purpose treatment. Start 2026-11-26 (anticipated); primary completion 2030-01-08 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 352 participants (planned count; ClinicalTrials.gov record NCT07839585, source copy `cardio:ctgov-nct07839585-2026-11-16`, retrieved 2026-11-18)
- Planned start: 2026-11-26 (anticipated) (ClinicalTrials.gov record NCT07839585, source copy `cardio:ctgov-nct07839585-2026-11-16`, retrieved 2026-11-18)
- Primary completion: 2030-01-08 (anticipated) (ClinicalTrials.gov record NCT07839585, source copy `cardio:ctgov-nct07839585-2026-11-16`, retrieved 2026-11-18)
- Completion: 2030-06-14 (anticipated) (ClinicalTrials.gov record NCT07839585, source copy `cardio:ctgov-nct07839585-2026-11-16`, retrieved 2026-11-18)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07839585-2026-11-16`, retrieved 2026-11-18)

## The registry's words

- Brief title: A Clinical Study of Sotatercept (MK-7962) in People With Combined Postcapillary and Precapillary Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction (MK-7962-041)
- Acronym: CHORUS
- Condition: Pulmonary Hypertension
- Intervention (Biological): Sotatercept
- Intervention (Biological): Placebo
- Lead sponsor: Merck Sharp & Dohme LLC
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Pulmonary hypertension (`cardio:pulmonary-hypertension`)
- Registry lists this organization as the lead sponsor: Merck Sharp & Dohme LLC (`cardio:org-merck-sharp-dohme-llc`)

## Provenance

Content hash: 7899206fb3a4f5d0235d23f3371f02df8dc070277da5c147dc58a24ee2f78470
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
